MX337656B - Metodos para el tratamiento y prevencion de disfuncion retinal relacionada con la edad. - Google Patents

Metodos para el tratamiento y prevencion de disfuncion retinal relacionada con la edad.

Info

Publication number
MX337656B
MX337656B MX2010008847A MX2010008847A MX337656B MX 337656 B MX337656 B MX 337656B MX 2010008847 A MX2010008847 A MX 2010008847A MX 2010008847 A MX2010008847 A MX 2010008847A MX 337656 B MX337656 B MX 337656B
Authority
MX
Mexico
Prior art keywords
age
prevention
treatment
methods
retinal dysfunction
Prior art date
Application number
MX2010008847A
Other languages
English (en)
Spanish (es)
Other versions
MX2010008847A (es
Inventor
Krzysztof Palczewski
Tadao Maeda
David Saperstein
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of MX2010008847A publication Critical patent/MX2010008847A/es
Publication of MX337656B publication Critical patent/MX337656B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2010008847A 2008-02-11 2009-02-10 Metodos para el tratamiento y prevencion de disfuncion retinal relacionada con la edad. MX337656B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2762508P 2008-02-11 2008-02-11
PCT/US2009/000824 WO2009102418A1 (en) 2008-02-11 2009-02-10 Methods for the treatment and prevention of age-related retinal dysfunction

Publications (2)

Publication Number Publication Date
MX2010008847A MX2010008847A (es) 2010-11-30
MX337656B true MX337656B (es) 2016-03-14

Family

ID=40521846

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008847A MX337656B (es) 2008-02-11 2009-02-10 Metodos para el tratamiento y prevencion de disfuncion retinal relacionada con la edad.

Country Status (14)

Country Link
US (7) US8324270B2 (enExample)
EP (1) EP2252276B1 (enExample)
JP (3) JP6022746B2 (enExample)
KR (2) KR101810381B1 (enExample)
CN (1) CN101969938A (enExample)
AU (1) AU2009213138B2 (enExample)
BR (1) BRPI0908154A2 (enExample)
CA (2) CA2714530C (enExample)
IL (2) IL207220B (enExample)
MX (1) MX337656B (enExample)
NZ (3) NZ587376A (enExample)
RU (1) RU2565448C2 (enExample)
WO (1) WO2009102418A1 (enExample)
ZA (1) ZA201005434B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242704A1 (en) * 2003-03-14 2004-12-02 University Of Washington, Techtransfer - Invention Licensing Stabilized mutant opsin proteins
EP2397131B1 (en) 2004-06-18 2019-09-11 University of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders
PT1888548E (pt) 2005-05-26 2012-10-30 Neuron Systems Inc Derivado de quinolina para o tratamento de doenças da retina
CA2714530C (en) * 2008-02-11 2018-09-25 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
US20120178806A1 (en) 2009-09-15 2012-07-12 Qlt Inc. Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
JP5885670B2 (ja) 2009-12-11 2016-03-15 アルデイラ セラピューティクス， インコーポレイテッド 黄斑変性の処置のための組成物および方法
KR20180043846A (ko) 2010-04-19 2018-04-30 노벨리언 테라퓨틱스 인코포레이티드 내인성 레티노이드 결핍과 연관된 시각 장애의 치료 또는 완화를 위한 치료 요법 및 방법
US8846723B2 (en) 2010-07-29 2014-09-30 Eastman Chemical Company Esters of O-substituted hydroxy carboxylic acids and preparations thereof
US8613940B2 (en) 2010-09-03 2013-12-24 Eastman Chemical Company Carbonate derivatives as skin care
US8329938B2 (en) * 2011-02-21 2012-12-11 Eastman Chemical Company Hydroxyalkanoic acid and hydroxyalkanoice acid oligomer esters of retinol
US10226536B2 (en) 2011-11-28 2019-03-12 Case Western Reserve University Polysaccharide therapeutic conjugates
CA2865935C (en) * 2012-03-01 2021-12-14 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
JP6514114B2 (ja) 2013-01-23 2019-05-15 アルデイラ セラピューティクス， インコーポレイテッド 毒性アルデヒド関連疾患および処置
US10471118B2 (en) 2014-05-30 2019-11-12 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
US11129845B2 (en) 2014-06-18 2021-09-28 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US10925980B2 (en) 2014-08-04 2021-02-23 Case Western Reserve University Molecular probes and methods of use
US11407786B2 (en) 2015-06-18 2022-08-09 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
WO2017035077A1 (en) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
US12060318B2 (en) 2015-10-09 2024-08-13 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
EP3454858A4 (en) 2016-05-09 2020-01-15 Aldeyra Therapeutics, Inc. COMBINATION TREATMENT OF FLAMMABLE CONDITIONS AND DISEASES OF THE EYE
AU2018234919A1 (en) 2017-03-16 2019-09-19 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
EP3694500A4 (en) 2017-10-10 2021-06-30 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
EP3962894A4 (en) 2019-05-02 2023-01-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND USES THEREOF
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
WO2021062022A1 (en) * 2019-09-25 2021-04-01 The Board Of Trustees Of The Leland Stanford Junior University Metabolic rescue of retinal degeneration
EP4149470A4 (en) 2020-05-13 2024-04-24 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
CN116056691A (zh) * 2020-06-09 2023-05-02 典晶生物医药科技(苏州)有限公司 使用每日低剂量的类视黄醇化合物治疗视觉障碍的方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3196076A (en) 1961-12-20 1965-07-20 Schering Corp Anti-depressant 10-(3-dimethylaminopropyl)-3-azaphenothiazine
US3196078A (en) * 1962-01-30 1965-07-20 Ortho Pharma Corp Process for combating retinits pigmentosa
US3517067A (en) 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
DE2300107C2 (de) 1973-01-03 1982-03-11 Basf Ag, 6700 Ludwigshafen Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen
DE2456959A1 (de) 1974-12-03 1976-06-16 Basf Ag 4-(e)- und 4-(z)-7-methyl-9-(2,6,6trimethyl-1-cyclohexen-1-yl)-nona-2,4,6,8tetraencarbonsaeure, ihre derivate und diese enthaltende zubereitungen
JPS61275266A (ja) 1985-05-28 1986-12-05 Taisho Pharmaceut Co Ltd レチノイド誘導体
US5310764A (en) 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
JPH06340525A (ja) 1993-06-02 1994-12-13 Lion Corp 安定な低眼刺激性ビタミンａ類可溶化点眼剤
CA2185699A1 (en) 1994-04-04 1995-10-12 William R. Freeman Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
RU2106843C1 (ru) 1994-06-29 1998-03-20 Красноярская государственная медицинская академия Способ лечения близорукости
JPH08198746A (ja) 1995-01-18 1996-08-06 Lion Corp 可溶化点眼剤
US5837728A (en) 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US5489611A (en) 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
US5620970A (en) 1995-06-05 1997-04-15 Alcon Laboratories, Inc. Topical ophthalmic carbonic anhydrase inhibitor formulations
US5716627A (en) 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
EP0908179A1 (en) 1997-08-23 1999-04-14 Werner Bollag Treatment of cell-mediated immune diseases
US6391924B1 (en) * 1997-12-10 2002-05-21 Hampar Karageozian Taurine derivatives useable in the treatment of ophthalmic disorders
US6552009B2 (en) 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US6372463B1 (en) 1999-05-06 2002-04-16 The President & Fellows Of Harvard College Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof
AU4993100A (en) 1999-05-07 2000-11-21 Chemlink Laboratories, Llc Window cleaner tablet
US6300328B1 (en) 1999-08-06 2001-10-09 Alcon Universal Ltd. Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
US20020028849A1 (en) 2000-04-18 2002-03-07 Godkin James D. Use of retinol in assisted-reproduction protocols
US6696069B2 (en) 2000-06-30 2004-02-24 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin care cosmetic compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof
EP1261623B1 (en) 2001-01-11 2009-11-04 Chebigen Inc. New retinol derivatives, the method of preparations and the uses thereof
AU2002240141A1 (en) 2001-01-26 2002-08-06 Steven Baranowitz Systemic formulations containing beta-carotene and derivatives thereof
GB0103998D0 (en) 2001-02-19 2001-04-04 King S College London Method
CA2442670A1 (en) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
EP1476147A4 (en) 2002-01-18 2005-03-09 Tatton Technologies Llc METHODS OF TREATING VIEW DISORDERS
US20030215413A1 (en) 2002-03-22 2003-11-20 L'oreal Compositions containing stabilized retinoid
US20040097587A1 (en) 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
US20030228277A1 (en) 2002-03-29 2003-12-11 Gehlsen Kurt R. Use of ROM production and release inhibitors to treat and prevent intraocular damage
US20040242704A1 (en) 2003-03-14 2004-12-02 University Of Washington, Techtransfer - Invention Licensing Stabilized mutant opsin proteins
JP2007525496A (ja) * 2004-02-17 2007-09-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 黄班変性症を含む眼科疾患の管理
RU2006133300A (ru) 2004-02-17 2008-03-27 Президент Энд Феллоуз Оф Гарвард Колледж (Us) Управление течением офтальмологических расстройств, включая дегенерацию желтого пятна
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
EP1727529B1 (en) 2004-03-17 2016-03-02 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
EP2397131B1 (en) 2004-06-18 2019-09-11 University of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders
GEP20084520B (en) 2004-06-23 2008-10-27 Sirion Therapeutics Inc Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
CA2575265A1 (en) * 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat ophthalmic disorders
WO2006039551A2 (en) 2004-09-30 2006-04-13 The Regents Of The University Of California Local administration of retinoids to treat deficiencies in dark adaptation
EP2687208A1 (en) 2007-09-12 2014-01-22 The Trustees of Columbia University in the City of New York Compositions and Methods for Treating Macular Degeneration
CA2714530C (en) 2008-02-11 2018-09-25 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction

Also Published As

Publication number Publication date
IL207220B (en) 2018-04-30
RU2565448C2 (ru) 2015-10-20
CN101969938A (zh) 2011-02-09
KR20160092032A (ko) 2016-08-03
JP2014221828A (ja) 2014-11-27
MX2010008847A (es) 2010-11-30
JP2016190852A (ja) 2016-11-10
US8324270B2 (en) 2012-12-04
AU2009213138B2 (en) 2014-11-06
US20190133986A1 (en) 2019-05-09
CA3018374A1 (en) 2009-08-20
JP5934304B2 (ja) 2016-06-15
JP2011511789A (ja) 2011-04-14
US9855239B2 (en) 2018-01-02
IL207220A0 (en) 2010-12-30
US20100035986A1 (en) 2010-02-11
CA2714530C (en) 2018-09-25
NZ587376A (en) 2012-06-29
US20130072558A1 (en) 2013-03-21
EP2252276A1 (en) 2010-11-24
US20180098955A1 (en) 2018-04-12
RU2010137842A (ru) 2012-03-20
US20130072557A1 (en) 2013-03-21
KR20100126358A (ko) 2010-12-01
US9408821B2 (en) 2016-08-09
BRPI0908154A2 (pt) 2015-08-11
JP6272943B2 (ja) 2018-01-31
IL258356A (en) 2018-05-31
US20160331713A1 (en) 2016-11-17
US9233091B2 (en) 2016-01-12
KR101810381B1 (ko) 2017-12-19
AU2009213138A1 (en) 2009-08-20
JP6022746B2 (ja) 2016-11-09
CA2714530A1 (en) 2009-08-20
US20130072561A1 (en) 2013-03-21
EP2252276B1 (en) 2019-03-27
NZ600498A (en) 2014-01-31
ZA201005434B (en) 2011-11-30
WO2009102418A1 (en) 2009-08-20
NZ617701A (en) 2015-06-26

Similar Documents

Publication Publication Date Title
MX337656B (es) Metodos para el tratamiento y prevencion de disfuncion retinal relacionada con la edad.
SG10201400685SA (en) Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia
ZA202110659B (en) Methods of reducing the risk of cardiovascular events in a subject
WO2013078440A3 (en) Enhanced treatment regimens using mtor inhibitors
SG10201908757TA (en) Boronic acids and esters as inhibitors of fatty amide hydrolase
MY187464A (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy using eicosapentaenoic acid ethyl ester
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
ECSP10010289A (es) Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada
WO2013085849A3 (en) Sulfate esters of noribogaine
MX2021011563A (es) Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen.
NZ596228A (en) Compositions and methods for the treatment of inflammation
PH12012501358A1 (en) Treatment method
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
MX2012002758A (es) Pirazinil-piridinas utiles para el tratamiento de enfermedades proliferativas.
EA201190337A1 (ru) Способ лечения
NZ707955A (en) Monohydrate of an azaadamantane derivative
NZ597030A (en) Method for treatment of diseases
WO2011050095A3 (en) Prevention and treatment of post-operative cognitive dysfunction (pocd)
WO2012145737A8 (en) Fatty acid amide hydrolase inhibitors for treating pain
MY156278A (en) Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones
TW201129361A (en) Methods for treating pain
MX2010013790A (es) Composiciones y metodos para tratar inflamacion de corneas.
PH12012501476A1 (en) Aminoquinoline derivatives
WO2008016665A3 (en) Imidazoacridine compounds for treating flt3 -mediated disorders
MX337593B (es) Gemcabeno y derivados para tratar la pancreatitis.

Legal Events

Date Code Title Description
FG Grant or registration